Floatz logo

Autologous Natural Killer Cell-Like Ctls

Stage II Fallopian Tube Cancer AJCC v8

Roswell Park Cancer InstituteCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

72 Active assets in the Stage II Fallopian Tube Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 2BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
TAMOXIFEN
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3BB

View all 50 →

Same molecule, other indications

Autologous Natural Killer Cell-Like Ctls is also rated in:

ovarian carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
primary peritoneal carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
fallopian tube cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →